Checkpoint Therapeutics Inc (CKPT) — Cash Flow-to-Debt Ratio
Checkpoint Therapeutics Inc (CKPT) has a Cash Flow-to-Debt Ratio of -0.65x as of March 2025, meaning its operating cash flow of $-11.69 Million could theoretically repay -1% of its total liabilities ($17.87 Million) in one year. See Checkpoint Therapeutics Inc free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Checkpoint Therapeutics Inc Cash Flow-to-Debt Ratio (2015–2024)
Historical debt coverage capacity for Checkpoint Therapeutics Inc across 10 annual periods. Also explore Checkpoint Therapeutics Inc annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Checkpoint Therapeutics Inc (2015–2024)
Year-by-year debt coverage analysis for Checkpoint Therapeutics Inc. For market capitalisation and broader financial context, see how much is Checkpoint Therapeutics Inc worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.55x | $-31.10 Million | $20.10 Million | ▲ +40.1% |
| 2023 | -2.58x | $-47.59 Million | $18.43 Million | ▼ -47.1% |
| 2022 | -1.76x | $-57.55 Million | $32.77 Million | ▼ -73.5% |
| 2021 | -1.01x | $-26.31 Million | $25.98 Million | ▲ +55.9% |
| 2020 | -2.29x | $-16.55 Million | $7.22 Million | ▲ +12.9% |
| 2019 | -2.63x | $-21.37 Million | $8.12 Million | ▼ -33.6% |
| 2018 | -1.97x | $-25.80 Million | $13.09 Million | ▲ +18.8% |
| 2017 | -2.43x | $-15.46 Million | $6.37 Million | ▲ +10.4% |
| 2016 | -2.71x | $-9.95 Million | $3.67 Million | ▼ -941.0% |
| 2015 | -0.26x | $-1.11 Million | $4.26 Million | — |